Advance Disease-Modifying Targets, Revolutionize BBB Delivery & Collaborate with Global Partners to Power the Next Frontier of Neuroscience Therapeutics in Korea
Korea is rapidly emerging as a global hub for CNS innovation, with advances spanning diverse modalities, BBB shuttling technologies and differentiated targets beyond Aβ and tau. As a result, pharma and venture interest has surged, with 2026 already witnessing major deals such as Fosun & AriBio, Insilico & SK Biopharmaceuticals and J&J & Prazer Therapeutics, highlighting the significant untapped potential to translate early-stage Korean assets into clinically successful, disease-modifying CNS therapies.
Capitalizing on this skyrocketing investment and innovation momentum, the World CNS Summit South Korea will bring together Korean pioneers like ABL Bio, AriBio and ADEL, alongside international powerhouses including Eli Lilly, Lundbeck, JCR Pharmaceuticals and Novartis to exchange ideas and foster the collaborations needed to drive a new wave of disease-modifying neuroscience therapies.
Hear from Your 2026 Speakers
전문 연사들의 이야기를 들어보세요
“I look forward to joining the World CNS Summit South Korea. It is a vital platform to engage with global experts on critical challenges in CNS disease research, and I am eager to share our progress in developing next-generation therapeutic solutions.”
Won-Suk Lee, Head of Business Development, ADEL
“I am excited to join the World CNS Summit South Korea and exchange ideas with researchers and industry leaders working to advance therapies for neurological disorders. I especially look forward to discussing the latest progress and future opportunities in antibody-oligonucleotide conjugates and CNS drug delivery technologies.”
Shinji Kumagai, Senior Scientist, JCR Pharmaceuticals
“The World CNS Summit South Korea comes at a pivotal moment for neurodegenerative drug development. I look forward to connecting with global leaders in Seoul to foster the cross-border collaborations and strategic partnerships that are essential to accelerating the delivery of next-generation neuroscience therapeutics to patients worldwide.”
Jae-Young, Senior Vice President, AriBio
"Angelini Pharma has built meaningful partnerships with several organizations across South Korea, and those collaborations have reinforced my belief in the power of regional teamwork in advancing CNS science. This summit is my opportunity to share those positive experiences, celebrate what we've learned together, and find new partners who are equally committed to making a real difference in brain health."
Rafal Kaminski, Chief Scientific Officer, Angelini Pharma
What Makes This Event Unique?
Korea’s First Industry-led Forum Dedicated to Neuroscience Drug Development:
100% Industry-Based Speaker Faculty
Full Focus On CNS, With Insights Spanning AD, PD, ALS, Epilepsy, Depression, & More
Global Pharma Representation, Attracting R&D & S&E Heads from Asia, US & Europe
Intimate Setting Built for Targeted Networking & Meaningful Collaboration
Explore the Full Event Guide
공식 아젠다를 다운로드하여 다음 내용을 확인하세요
- Cutting-edge insights from pioneering Korean innovators, alongside voices from Japan, China, US, India and Europe
- Presentations containing new data from AriBio, Mthera Pharma, ADEL, JCR Pharmaceuticals, Genuv and more
- Dedicated networking opportunities with global experts working on neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders
- Strategic investment insights from global representatives at Novartis, Takeda, Eli Lilly, Johnson & Johnson and more
Attending Companies Include
참석 기업에는 다음이 포함됩니다
Explore Related Events
관련 행사 둘러보기
Explore the Agenda
Hear the latest CNS innovations taking place within South Korea while hearing from global experts.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean neuroscience drug developers.
Join Biopharma Experts
Be part of the hottest conversations with like-minded neuroscientists, C-level executives, heads, VPs, and more across discovery, translational and clinical development.